Karlsson, Kasper
Przybilla, Moritz J. http://orcid.org/0000-0001-5645-9492
Kotler, Eran http://orcid.org/0000-0002-1463-7462
Khan, Aziz http://orcid.org/0000-0002-6459-6224
Xu, Hang
Karagyozova, Kremena
Sockell, Alexandra
Wong, Wing H.
Liu, Katherine http://orcid.org/0000-0002-9616-9403
Mah, Amanda
Lo, Yuan-Hung
Lu, Bingxin http://orcid.org/0000-0002-0606-5150
Houlahan, Kathleen E.
Ma, Zhicheng
Suarez, Carlos J.
Barnes, Chris P. http://orcid.org/0000-0002-9459-1395
Kuo, Calvin J. http://orcid.org/0000-0002-7427-5985
Curtis, Christina http://orcid.org/0000-0003-0166-3802
Article History
Received: 1 September 2022
Accepted: 19 April 2023
First Online: 31 May 2023
Competing interests
: Unrelated to this study, C.J.K. is a founder and stockholder for Surrozen, Inc., Mozart Therapeutics and NextVivo, Inc. and C.C. is a stockholder in Illumina and DeepCell and an advisor to DeepCell, Genentech, Bristol Myers Squibb, 3T Biosciences, NanoString and ResistanceBio. The remaining authors declare no competing interests.